Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
Stock Information for Outlook Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.